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Depression is a common and debilitating psychiatric syndrome with a complex risk architecture marked by
interacting genetic and environmental factors. In this issue of Neuron, the study by Kohli et al. (2011) reports
a novel genome-wide supported risk variant for depression that affects hippocampal gene expression,
anatomy, and biochemistry.Major depressive disorder (MDD) is a
common illness with a lifetime prevalence
of 17% in the general population and
a leading cause of disability worldwide
(McKenna et al., 2005). Enormous direct
and indirect costs, the severe burden on
those afflicted and their families, and
strongly increased mortality from suicide
andcomplicating somatic illnesses under-
score the urgent need for better diagnosis
and treatment. Since depression was
recognized as a complex brain disorder
in the 1950s, early research often focused
onneurochemical aspectsof thecondition
such as monoaminergic neurotransmis-
sion. This strategy was suggested by the
mechanisms of action of antidepressant
drugs discovered serendipitously during
that time (Ketter et al., 1996). In recent
years, the availability of novel research
technologies has enabled a broader view
ofMDD that integrates additional neurobi-
ological dimensions, in particular those
derived from molecular genetics and
neuroimaging. In line with this conceptual
shift, depression is now conceptualized
as a biologically heterogeneous behav-
ioral endpoint of the adverse interaction
of susceptibility genes and environmental
factors. This risk constellation, in turn, trig-
gers a complex cascade of intermediate
biological changes in gene expression,
cellular physiology, and neurochemistry
that impacts on multiple interconnected
neural networks (Meyer-Lindenberg and
Weinberger, 2006).
On the systems level, converging neuro-
imaging evidence points to a prominent
role of the cortical-limbic circuits in the
pathophysiology of the disease. Specifi-
cally, milestone work by the Mayberggroup has identified a key neural node for
depression in the subgenual anterior
cingulate cortex (ACC), which regulates
downstream limbic sites such as hippo-
campus and amygdala. This research has
been successfully translated into new
interventional strategies, notably deep-
brain stimulation near the subgenual ACC
of patients with a poor response to con-
ventional pharmacotherapy (Mayberg,
2009). Given the heritable component of
the disorder, the question has been asked
whether candidate risk gene variants
modulate the function of these cortical-
limbic networks (Munafo` et al., 2008).
Often, the answer has been yes: for ex-
ample, abnormalities in the interregional
coupling of ACC and amygdala have
been found in short-allele carriers of the
50 promoter polymorphismof the serotonin
transporter gene (Pezawas et al., 2005).
Properties of this neural circuit also pre-
dicted trait anxiety, a temperamental fea-
tureassociatedwithdepression, indicating
that this genetic variant affects a systems-
level mechanism linked to the disease.
Importantly, the cortical-limbic circuitry is
not only modulated by genetic but also
environmental risk factors: chronic stress
impacts on the amygdala, hippocampus,
medial prefrontal cortex, and their reg-
ulatory interactions, which are important
for neural plasticity functions such as
neural extinction, a crucial coping mecha-
nism for environmental adversity (Pezawas
et al., 2005).
Candidate gene studies, however, have
been criticized because the evidence for
association with the illness phenotype is
ambiguous. This objection can be partly
addressed through genome-wide as-Neuronsociation (GWA) studies, which provide
hypothesis-free support for susceptibility
variants that survive the severe statistical
correction procedures necessary with
this approach. Genome-wide significant
variants associated with other mood
disorders have in fact been found to
impact limbic and medial prefrontal regu-
latory regions (Wessa et al., 2010). In the
optimal case, a genome-wide study will
identify a truly novel genome-wide sup-
ported risk variant for psychiatric illness,
demonstrate its functional impact in key
neural systems of the disease, aim to
address the impact of environmental
factors, and provide clues about future
treatment targets.
Many of these hopes are realized in the
work by Kohli at al. (2011) in this issue of
Neuron. Following a GWA strategy in a
Caucasian sample of 353 index cases
and 366 healthy controls, the authors
identify a new genome-wide supported
risk variant (rs1545843) for MDD on chro-
mosome 12q21.31. Through replication in
a meta-analysis across six independent
samples, confidence in the robustness
of the reported disease association is
considerable. This finding is all the more
important as prior GWA studies failed to
identify susceptibility variants of MDD on
a genome-wide supported level of signifi-
cance (Lewis et al., 2010; Shi et al., 2011).
As is often the case, the identified poly-
morphism in the Kohli study maps to
a chromosomal ‘‘desert area’’ outside any
annotated gene, which complicates the
process of finding a biologically mean-
ingful interpretation of the finding. This
highlights the crucial relevance of imple-
mentingmultiple, interrelated intermediate70, April 28, 2011 ª2011 Elsevier Inc. 171
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Previewsphenotype studies to help assign a func-
tion to the initial genetic result. Based on
the relative proximity, the authors hypoth-
esized a regulatory effect of the variant on
the expression of a gene of the solute
carrier 6 family (SLC6A15), a sodium-
dependent high-affinity transporter for
large amino acids in the central nervous
system (Bro¨er et al., 2006). In linewith their
expectations, the authors demonstrate
a significant decrease in expression of
the full-length SLC6A15 mRNA isoform in
rs1545843 risk allele carriers by using
a valuable resource, human premortem
hippocampal tissue.
The access to this material is especially
useful because prior evidence relates
stress-induced impairments in hippo-
campal neuroplasticity to the expression
of cognitive and affective deficits in MDD.
Notably, these processes have been
convincingly linked to alterations in gluta-
mate neurotransmission, which is critical
for the neuroplasticity and anatomy of the
hippocampus (Fuchs et al., 2004). Inter-
estingly, proline, a precursor for glutamate
synthesis, is the substrate with the highest
affinity for the SLC6A15 transporter. Thus,
these findingsmay indicate a potential risk
mechanism linking SLC6A15 genotype
and environmental stressors to limbic
dysregulation in glutamateneurotransmis-
sion and ultimately to psychopathology.
To probe the theory of a modulation
of SLC6A15 function by environmental
factors such as chronic stress, the authors
expand their analysis to theexaminationof
gene expression in the hippocampus of an
establishedmousemodel of stress vulner-
ability and resilience. In line with their
hypothesis,Kohli et al. (2011)demonstrate
a significant and specific reduction of
SLC6A15 mRNA expression in stress-
susceptible mice.
Finally, by adding yet two other interme-
diate phenotype levels, Kohli et al. (2011)
extend their scope from genetic associa-
tion and gene expression to in vivo
biomarkers of the human brain and ex-
amine the impact of the identified suscepti-
bility variant on hippocampus anatomy172 Neuron 70, April 28, 2011 ª2011 Elsevierand neurochemistry. By using automated
brain morphometry, the authors provide
evidence for significant genotype-by-diag-
nosis interaction effects of rs1545843 on
hippocampus volume: a disproportionally
pronounced gray matter decrease in the
bilateral cornus ammonis was seen in
MDD patients carrying the risk allele (A/A).
This finding is supported by evidence
from a proton magnetic resonance spec-
troscopy study, where the authors de-
monstrate lower levels of the molecules
N-acetyl-aspartate and glutamate and/or
glutamine in the hippocampus of healthy
risk-allele carriers. These molecules are
thought to be markers of neuronal viability
and glutamate signaling. It is interesting to
speculate that these measures of gluta-
mate metabolism, altered already in
healthy controls, may index an effect close
to theactionof the riskgene identified in the
present study, whereas hippocampal vol-
ume deficits, visible only in patients, could
require additional genetic or environmental
risk factors that must, by definition, have
been more numerous in the participants
with MDD.
Overall, the work by the consortium re-
ported in Kohli at al. (2011) provides a
remarkablebodyofneuroscienceevidence
linking rs1545843, a novel genome-wide
supported risk variant, to the pathophysi-
ology of MDD. In doing so, the authors
cover several interconnected intermediate
phenotype levels that provide, in their
entirety, new insights into the pathophysi-
ology of depression. Notably, this genetic
approach ended up defining a system
susceptible to environmental risk factors
such as chronic stress, which re-empha-
sizes thecrucial relevanceofgene-environ-
mental interactions to the pathophysiology
of depression. Given this premise, future
studies should further extend this research,
for example from testing regionally driven
hypotheses to the examination of entire
functional networks, such as investigation
of dynamic aspects of neural circuits
involving the hippocampus. The effects of
gene-environment interactions on corti-
cal-limbic processing circuits to whichInc.glutamate is a critical contributor should
also be examined. Because the work by
Kohli et al. (2011) points to glutamate
dysfunction as likely mediator of these
complex susceptibility effects, these func-
tional biomarkers may aid both the devel-
opment and neuroimaging-guided evalua-
tion of innovative new pharmacological
approaches, which modulate, directly or
indirectly, the adverse downstream effects
of glutamate dysfunction in mood regula-
tory circuits.REFERENCES
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